ERJ
HOME HELP FEEDBACK SUBSCRIPTIONS ARCHIVE SEARCH TABLE OF CONTENTS
QUICK SEARCH:   [advanced]


     

This Article
Right arrow Full Text (PDF)
Right arrow Alert me when this article is cited
Right arrow Alert me if a correction is posted
Services
Right arrow Email this article to a friend
Right arrow Similar articles in this journal
Right arrow Similar articles in PubMed
Right arrow Alert me to new issues of the journal
Right arrow Download to citation manager
Citing Articles
Right arrow Citing Articles via HighWire
Right arrow Citing Articles via Google Scholar
Google Scholar
Right arrow Articles by Primhak, R.
Right arrow Articles by Efthimiou, J
Right arrow Search for Related Content
PubMed
Right arrow PubMed Citation
Right arrow Articles by Primhak, R.
Right arrow Articles by Efthimiou, J
Eur Respir J 1999; 13: 78-81
Copyright © ERS Journals Ltd 1999

Clinical Trial

The bronchoprotective effect of inhaled salmeterol in preschool children: a dose-ranging study

RA Primhak, CM Smith, SC Yong, R Wach, M Kurian, R Brown, and J Efthimiou

The optimal dose of salmeterol in infants and preschool children is not known. The aim of this study was to assess the bronchoprotective effect of different doses of salmeterol using methacholine-induced wheeze in children aged <4 yrs. Children <4 yrs old with a history of recurrent wheeze underwent two methacholine challenges within 7 days. One hour before each challenge they were pretreated in double-blind fashion using a metered-dose inhaler and Babyhaler spacer. Placebo was given before one challenge, and either 25, 50 or 100 microg of salmeterol before the other. Both the dose and treatment order were random. The provocative concentration of methacholine causing wheeze (PCwheeze) was measured on each occasion. Studies were terminated when wheeze occurred or arterial oxygen saturation (Sa,o2) fell below 91%. Of the 42 children enrolled, 33 completed the study. Two subjects refused the challenge test, two failed to return and five developed upper respiratory tract infections or wheeze between the two tests. The mean (range) age of the population was 27 (8-46) months. Ratios of PCwheeze between treatment and placebo challenges were calculated for each dosage group. The treatment/placebo ratios (95% confidence intervals) were 1.2 (0.6-2.4) for 25 microg, 2.5 (1.4-4.6) for 50 microg (p<0.01), and 4.0 (2.1-7.4) (p<0.001) for 100 microg doses. In recurrently wheezy children aged <4 yrs a single dose of salmeterol between 25 and 100 microg has a dose-dependent effect on methacholine-induced wheeze, and this is significantly different from placebo at 50 and 100 microg. This study suggests that the Babyhaler effectively delivers salmeterol to children <4 yrs of age and that doses between 50-100 microg are efficacious.


This article has been cited by other articles:


Home page
 Eur Respir JHome page
P. L. P. Brand, E. Baraldi, H. Bisgaard, A. L. Boner, J. A. Castro-Rodriguez, A. Custovic, J. de Blic, J. C. de Jongste, E. Eber, M. L. Everard, et al.
Definition, assessment and treatment of wheezing disorders in preschool children: an evidence-based approach
Eur. Respir. J., October 1, 2008; 32(4): 1096 - 1110.
[Abstract] [Full Text] [PDF]

Home page
 Postgrad. Med. J.Home page
J Grigg
Management of paediatric asthma
Postgrad. Med. J., September 1, 2004; 80(947): 535 - 540.
[Abstract] [Full Text] [PDF]

Home page
 ThoraxHome page
C. Byrnes, S. Shrewsbury, P. J Barnes, and A. Bush
Salmeterol in paediatric asthma
Thorax, September 1, 2000; 55(9): 780 - 784.
[Abstract] [Full Text]


HOME HELP FEEDBACK SUBSCRIPTIONS ARCHIVE SEARCH TABLE OF CONTENTS
Copyright © 1999 by the European Respiratory Society.